ReviewCancers2021
Clinical Utility of
Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- ESR Essentials: role of PET/CT in neuroendocrine tumors-practice recommendations by the European Society for Hybrid, Molecular and Translational Imaging.European radiology · 2025Guideline
- Grading and detecting gastroenteropancreatic neuroendocrine neoplasms with dual-tracer ( 18 F-AlF-NOTA-octreotide/ 18 F-FDG) PET/CT: a metabolic parameter-based study.Nuclear medicine communications · 2026Article
- Efficacy of peptide receptor radionuclide therapy in patients with oligodiscordant gastroenteropancreatic neuroendocrine tumours.European journal of nuclear medicine and molecular imaging · 2026Article
- Whole genome and exome sequencing of pancreatic neuroendocrine tumour to investigate PRRT response.Endocrine-related cancer · 2026Article
- Comparing Response Evaluation Methods for PRRT in Neuroendocrine Tumors: Insights from an Exploratory Study.Cancers · 2026Article
- Article
- The impact of radioligand therapy on prognosis in patients with lung neuroendocrine tumors.Frontiers in endocrinology · 2026Article
- Article
- Tumor-to-tumor metastasis: case report of a neuroendocrine tumor of the lung metastasizing to a benign oncocytoma of the kidney.The Canadian journal of urology · 2025Article
- One-day dual-tracer examination in neuroendocrine neoplasms: a real advantage of low activity LAFOV PET imaging.European journal of nuclear medicine and molecular imaging · 2025Article
- Article
- The role of combined FDG and SST PET/CT in neuroendocrine tumors.Journal of neuroendocrinology · 2025Review
- Endocrinology application of molecular imaging: current role of PET/CT.Journal of endocrinological investigation · 2024Review
- Radionuclide Theranostics in Neuroendocrine Neoplasms: An Update.Current oncology reports · 2024Review
- A Comprehensive Review on Neuroendocrine Neoplasms: Presentation, Pathophysiology and Management.Journal of clinical medicine · 2023Review
- Advances in PET imaging of cancer.Nature reviews. Cancer · 2023Review
- Integrating Theranostics Into Patient Care Pathways:AJR. American journal of roentgenology · 2023Review
- Pancreatic neuroendocrine tumors: tailoring imaging to specific clinical scenarios.Abdominal radiology (New York) · 2023Review
- Recent Therapeutic Advances in Pituitary Carcinoma.Journal of immunotherapy and precision oncology · 2023Review
- Treatment modalities favoring outcome in well-differentiated neuroendocrine tumors G3.Frontiers in endocrinology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The role of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.